288 related articles for article (PubMed ID: 24441150)
1. Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial.
Yamanaka H; Ishiguro N; Takeuchi T; Miyasaka N; Mukai M; Matsubara T; Uchida S; Akama H; Kupper H; Arora V; Tanaka Y
Rheumatology (Oxford); 2014 May; 53(5):904-13. PubMed ID: 24441150
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.
Takeuchi T; Yamanaka H; Ishiguro N; Miyasaka N; Mukai M; Matsubara T; Uchida S; Akama H; Kupper H; Arora V; Tanaka Y
Ann Rheum Dis; 2014 Mar; 73(3):536-43. PubMed ID: 23316080
[TBL] [Abstract][Full Text] [Related]
3. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis.
Keystone EC; van der Heijde D; Kavanaugh A; Kupper H; Liu S; Guérette B; Mozaffarian N
J Rheumatol; 2013 Sep; 40(9):1487-97. PubMed ID: 23818718
[TBL] [Abstract][Full Text] [Related]
4. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension.
Keystone EC; Breedveld FC; van der Heijde D; Landewé R; Florentinus S; Arulmani U; Liu S; Kupper H; Kavanaugh A
J Rheumatol; 2014 Jan; 41(1):5-14. PubMed ID: 24241487
[TBL] [Abstract][Full Text] [Related]
5. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis.
Emery P; Genovese MC; van Vollenhoven R; Sharp JT; Patra K; Sasso EH
J Rheumatol; 2009 Jul; 36(7):1429-41. PubMed ID: 19369462
[TBL] [Abstract][Full Text] [Related]
6. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.
Smolen JS; Emery P; Fleischmann R; van Vollenhoven RF; Pavelka K; Durez P; Guérette B; Kupper H; Redden L; Arora V; Kavanaugh A
Lancet; 2014 Jan; 383(9914):321-32. PubMed ID: 24168956
[TBL] [Abstract][Full Text] [Related]
7. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study.
Kavanaugh A; Fleischmann RM; Emery P; Kupper H; Redden L; Guerette B; Santra S; Smolen JS
Ann Rheum Dis; 2013 Jan; 72(1):64-71. PubMed ID: 22562973
[TBL] [Abstract][Full Text] [Related]
8. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
[TBL] [Abstract][Full Text] [Related]
9. Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study.
Keystone EC; Haraoui B; Guérette B; Mozaffarian N; Liu S; Kavanaugh A
J Rheumatol; 2014 Feb; 41(2):235-43. PubMed ID: 24293583
[TBL] [Abstract][Full Text] [Related]
10. Analysis of integrated radiographic data from two long-term, open-label extension studies of adalimumab for the treatment of rheumatoid arthritis.
Landewé R; Østergaard M; Keystone EC; Florentinus S; Liu S; van der Heijde D
Arthritis Care Res (Hoboken); 2015 Feb; 67(2):180-6. PubMed ID: 25073879
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial.
Soubrier M; Puéchal X; Sibilia J; Mariette X; Meyer O; Combe B; Flipo RM; Mulleman D; Berenbaum F; Zarnitsky C; Schaeverbeke T; Fardellone P; Dougados M
Rheumatology (Oxford); 2009 Nov; 48(11):1429-34. PubMed ID: 19741011
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Blanco R; Kadva A; Dimonaco S
Ann Rheum Dis; 2017 Jul; 76(7):1279-1284. PubMed ID: 28389552
[TBL] [Abstract][Full Text] [Related]
13. Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis.
Keystone EC; Kavanaugh A; Weinblatt ME; Patra K; Pangan AL
J Rheumatol; 2011 May; 38(5):855-62. PubMed ID: 21285171
[TBL] [Abstract][Full Text] [Related]
14. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
[TBL] [Abstract][Full Text] [Related]
15. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER.
van der Heijde D; Breedveld FC; Kavanaugh A; Keystone EC; Landewé R; Patra K; Pangan AL
J Rheumatol; 2010 Nov; 37(11):2237-46. PubMed ID: 20889601
[TBL] [Abstract][Full Text] [Related]
16. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.
Moreland LW; O'Dell JR; Paulus HE; Curtis JR; Bathon JM; St Clair EW; Bridges SL; Zhang J; McVie T; Howard G; van der Heijde D; Cofield SS;
Arthritis Rheum; 2012 Sep; 64(9):2824-35. PubMed ID: 22508468
[TBL] [Abstract][Full Text] [Related]
17. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
Detert J; Bastian H; Listing J; Weiß A; Wassenberg S; Liebhaber A; Rockwitz K; Alten R; Krüger K; Rau R; Simon C; Gremmelsbacher E; Braun T; Marsmann B; Höhne-Zimmer V; Egerer K; Buttgereit F; Burmester GR
Ann Rheum Dis; 2013 Jun; 72(6):844-50. PubMed ID: 22739990
[TBL] [Abstract][Full Text] [Related]
18. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
Breedveld FC; Weisman MH; Kavanaugh AF; Cohen SB; Pavelka K; van Vollenhoven R; Sharp J; Perez JL; Spencer-Green GT
Arthritis Rheum; 2006 Jan; 54(1):26-37. PubMed ID: 16385520
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
Strand V; Rentz AM; Cifaldi MA; Chen N; Roy S; Revicki D
J Rheumatol; 2012 Jan; 39(1):63-72. PubMed ID: 22045836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
